ATE281835T1 - Fettemulsion, die ein xanthinderivat enthält - Google Patents

Fettemulsion, die ein xanthinderivat enthält

Info

Publication number
ATE281835T1
ATE281835T1 AT97934737T AT97934737T ATE281835T1 AT E281835 T1 ATE281835 T1 AT E281835T1 AT 97934737 T AT97934737 T AT 97934737T AT 97934737 T AT97934737 T AT 97934737T AT E281835 T1 ATE281835 T1 AT E281835T1
Authority
AT
Austria
Prior art keywords
fat emulsion
xanthine derivative
emulsion containing
hydroxyl
substituted
Prior art date
Application number
AT97934737T
Other languages
English (en)
Inventor
Toshihito Hosokawa
Kenji Iwata
Yuji Kawaguchi
Yasuki Kato
Kunio Ito
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE281835T1 publication Critical patent/ATE281835T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Edible Oils And Fats (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97934737T 1996-08-07 1997-08-07 Fettemulsion, die ein xanthinderivat enthält ATE281835T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22439996 1996-08-07
PCT/JP1997/002773 WO1998005334A1 (fr) 1996-08-07 1997-08-07 Emulsion grasse contenant un derive de xanthine

Publications (1)

Publication Number Publication Date
ATE281835T1 true ATE281835T1 (de) 2004-11-15

Family

ID=16813150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934737T ATE281835T1 (de) 1996-08-07 1997-08-07 Fettemulsion, die ein xanthinderivat enthält

Country Status (15)

Country Link
US (1) US6210687B1 (de)
EP (1) EP0958821B1 (de)
JP (2) JP4179631B2 (de)
KR (1) KR20000029672A (de)
CN (1) CN1227490A (de)
AT (1) ATE281835T1 (de)
AU (1) AU3784597A (de)
CA (1) CA2262578A1 (de)
DE (1) DE69731556T2 (de)
DK (1) DK0958821T3 (de)
ES (1) ES2232877T3 (de)
NZ (1) NZ334299A (de)
PT (1) PT958821E (de)
SI (1) SI0958821T1 (de)
WO (1) WO1998005334A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123538A1 (en) * 2000-12-29 2002-09-05 Peiguang Zhou Hot-melt adhesive based on blend of amorphous and crystalline polymers for multilayer bonding
US20040229901A1 (en) 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
CN1859913A (zh) * 2003-04-25 2006-11-08 美国诺华卡迪亚公司 改善肾功能损伤个体多尿症的方法
EP1932529A1 (de) 2003-04-25 2008-06-18 Novacardia, Inc. Verfahren zur verbesserten Harnausscheidung bei Personen mit beeinträchtiger Nierenfunktion
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
US20050239759A1 (en) * 2004-04-16 2005-10-27 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor
EP1928414A2 (de) * 2005-04-22 2008-06-11 Novacardia, Inc. Herstellung von emulsionen zur intravenösen injektion von wasserunlöslichen pharmazeutischen zusammensetzungen
ES2388786T3 (es) * 2005-08-15 2012-10-18 Provimi Holding B.V. Uso de estimulantes psicomotores y composiciones que los contienen en un método de tratamiento de mamíferos placentarios parturientes para reducir agotamiento materno y/o uterino
US7893070B2 (en) 2005-08-15 2011-02-22 Provimi Holding B.V. Method of treating parturient placental mammals in order to reduce maternal and/or uterine exhaustion
CA2633372A1 (en) * 2005-12-14 2007-06-21 Kyowa Hakko Kogyo Co., Ltd. Easily absorbed oral preparations of xanthine derivatives
CA2648281A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
WO2012051116A1 (en) 2010-10-12 2012-04-19 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146621A (en) * 1973-01-16 1979-03-27 The Regents Of The University Of Michigan Process of treating proliferative skin diseases
JPH0647533B2 (ja) * 1984-08-10 1994-06-22 裕 水島 ４−ビフエニリル酢酸系化合物含有脂肪乳剤
ATE74009T1 (de) * 1986-08-11 1992-04-15 American Cyanamid Co Zusammensetzungen zur parenteralen verabreichung und deren verwendung.
JPH0559056A (ja) * 1991-02-25 1993-03-09 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
WO1994016702A1 (fr) * 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'elimination irreguliere des matieres fecales
US5395836A (en) * 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
JP3729874B2 (ja) * 1993-04-07 2005-12-21 協和醗酵工業株式会社 キサンチン誘導体
JPH07285863A (ja) * 1994-02-25 1995-10-31 Takeda Chem Ind Ltd 注射剤組成物およびその製造方法
JPH0881360A (ja) * 1994-07-13 1996-03-26 Wakamoto Pharmaceut Co Ltd 安定な脂肪乳剤
JP4008965B2 (ja) * 1994-07-29 2007-11-14 昭和産業株式会社 レシチン含有脂肪乳剤の調製法
JPH08104620A (ja) * 1994-10-05 1996-04-23 Green Cross Corp:The 薬物含有脂肪乳剤

Also Published As

Publication number Publication date
AU3784597A (en) 1998-02-25
KR20000029672A (ko) 2000-05-25
JP4179631B2 (ja) 2008-11-12
DE69731556D1 (de) 2004-12-16
CN1227490A (zh) 1999-09-01
EP0958821A4 (de) 2003-05-02
JP2008231117A (ja) 2008-10-02
DK0958821T3 (da) 2005-01-03
CA2262578A1 (en) 1998-02-12
WO1998005334A1 (fr) 1998-02-12
DE69731556T2 (de) 2005-10-27
ES2232877T3 (es) 2005-06-01
EP0958821A1 (de) 1999-11-24
NZ334299A (en) 1999-05-28
PT958821E (pt) 2005-02-28
US6210687B1 (en) 2001-04-03
SI0958821T1 (en) 2005-02-28
EP0958821B1 (de) 2004-11-10

Similar Documents

Publication Publication Date Title
DE69628276D1 (de) Zubereitung von xanthinderivaten als feste dispersion
PT705833E (pt) Derivado de dc-89
DE69731556D1 (de) Fettemulsion, die ein xanthinderivat enthält
ATE226201T1 (de) Substituierte pyridylpyrazole
EP0711768A4 (de) Benzimidazol-derivate
ATE176470T1 (de) Xanthinderivate
AU9281198A (en) Benzofuran derivatives
KR890008150A (ko) 퀴놀린 카르본산 유도체
PT843679E (pt) Derivados da1-(piperidinil 1,2-disubstituido)-(4-imidazole fundido)-piperidina
KR850006187A (ko) 신규 히달토인(Hydantoin) 유도체의 제조방법
EP1031556A4 (de) 2-phenoxyanilin-derivate
CA2092919A1 (en) Epoxysuccinamic acid derivatives
DE69906243T2 (de) 2-Indanmethanolderivate und ihre Verwendung als Riechstoffe
DE69631521D1 (de) Propenonderivate
DE69222818D1 (de) Kondensierte Naphthyridinderivate
EP0626369A4 (de) Benzolsulfonamid derivate.
KR890009887A (ko) 이미다졸 유도체
DE69231244D1 (de) Pyrazolothiazolopyrimidin-derivate
DK0661273T3 (da) Indanderivater og fremgangsmåder til fremstilling af samme
KR890005110A (ko) 신규의 3-아로일-6,7-디히드로-5h-피롤로[1,2-c]이미다졸-7-카르복시산유도체
KR880001578A (ko) 안식향산 유도체
EP0614897A4 (de) Imidazonaphthyridin derivat.
KR870007879A (ko) 노르보르난계 술폰아미드 유도체의 제조방법
ATE79259T1 (de) Prophylaktische und heilende zusammensetzung enthaltende eine 8-chlorbenzothiazepin-verbindung und dessen verwendung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0958821

Country of ref document: EP

EEFA Change of the company name
REN Ceased due to non-payment of the annual fee